Stock BIOM3 BIOMM S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Biomm S.A.

Equities

BIOM3

BRBIOMACNOR2

Delayed Sao Paulo
Other stock markets
 02:57:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
16.73 BRL +2.26% Intraday chart for Biomm S.A. -4.40% +189.45%
May. 16 Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 18 Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil
MT
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A
CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, A Stelara Biosimilar
CI
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Lupin Enters Partnership to Market Biosimilar Pegfilgrastim in Brazil
MT
Biomm S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days
CI
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications
CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIOM3 Stock
  4. News Biomm S.A.
  5. Highlights